

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/990,909
				Filing Date	November 16, 2001
				First Named Inventor	Joan M. Fallon
				Art Unit	1645
Examiner Name	Virginia Allen Portner				
Sheet	1	of	4	Attorney Docket Number	41012-705.201

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Document Number	Application Date	Name of Patente or Applicant or Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code (if known)	MM-DD-YYYY			
	1.	US 13/002,136	Appln filed 12/30/10	Fallon		
	2.	US 2002/0037284 A1	03/01/2002	Fallon		
	3.	US 2002/0090653 A1	07/11/2002	Fallon		
	4.	US 2004/0071683 A1	04/15/2004	Fallon		
	5.	US 2004/0101562 A1	05/27/2004	Maio		
	6.	US 2004/0121002 A1	06/24/2004	Lee et al.		
	7.	US 2006/0182728 A1	08/17/2006	Fallon		
	8.	US 2006/0183180 A1	08/17/2006	Fallon		
	9.	US 2006/0198838 A1	09/07/2006	Fallon		
	10.	US 2007/0116695 A1	05/24/2007	Fallon		
	11.	US 2008/0058282 A1	03/06/2008	Fallon		
	12.	US 2008/0152637 A1	06/26/2008	Fallon		
	13.	US 2008/0161265 A1	07/03/2008	Fallon et al.		
	14.	US 2008/0219966 A1	09/11/2008	Fallon		
	15.	US 2008/0279839 A1	11/13/2008	Schuler et al.		
	16.	US 2009/0130081 A1	05/21/2009	Fallon		
	17.	US 2009/0197289 A1	08/06/2009	Fallon		
	18.	US 2009/0232789 A1	09/17/2009	Fallon		
	19.	US 2009/0263372 A1	10/22/2009	Fallon		
	20.	US 2009/0285790 A1	11/19/2009	Fallon		
	21.	US 2009/0286270 A1	11/19/2009	Fallon		
	22.	US 2009/0324572 A1	12/31/2009	Fallon		
	23.	US 2009/0324730 A1	12/31/2009	Fallon		
	24.	US 2010/0092447 A1	04/15/2010	Fallon		
	25.	US 2010/0169409 A1	07/01/2010	Fallon et al.		
	26.	US 2010/0233218 A1	09/16/2010	Fallon		
	27.	US 2010/0260857 A1	10/14/2010	Fallon et al.		
	28.	US 3,002,883	10/03/1961	Butt et al.		
Examiner Signature				Date Considered		

*EXAMINER: Insert if reference is cited, whether or not citation is in compliance with SOEP 604. Draw line through citation if not to be considered and not considered. Include only if this form with next consecutive to applicant. *Applicant's unique patent designation number (optional). *See Kind Code of USPTO Patent Documents at uspto.gov or MPEP 901.04. *Erase Office list issued the documents by the most recent (USPTO Standard ST-A1). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST-16 if possible. *Applicant is to state if applicable, the date of the document. *If English language translation is attached.

This information is required by 37 CFR 1.97 and 1.98. The information is required to retain or retain a benefit by the public which is to the (and by the USPTO) to prepare an application. The Secretary is governed by 35 U.S.C. 102 and 37 CFR 1.14. This information is required to take 1 hour in completing, gathering, creating, and submitting the completed application form in the USPTO. There will vary depending upon the individual case. Any changes to the format of this form require to complete this form and by suggestion for including this packet, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FIRM OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9191 (1-800-766-9191) and select option 3.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/990,909
				Filing Date	November 16, 2001
				First Named Inventor	Joan M. Fallon
				Art Unit	1645
Examiner Name	Virginia Allen Portner				
Sheet	2	of	4	Attorney Docket Number	41012-705 201

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number-Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	29.	US 5,324,514	06/28/1994	Sipos	
	30.	US 5,437,319	08/01/1995	Garugliori	
	31.	US 6,011,001	01/04/2000	Navia et al.	
	32.	US 6,743,447	06/01/2004	Laberge et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Country Code - Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ¹
	33.	WO 2002/014537 A2	02/21/2002	Fallon		
	34.	WO 2002/014537 A3	05/10/2002	Fallon		
	35.	WO 2009/114757 A2	09/17/2009	Fallon		
	36.	WO 2010/002972 A1	01/07/2010	Fallon		
	37.	WO 2010/080830 A1	07/15/2010	Fallon et al.		
	38.	WO 2010/080835 A1	07/15/2010	Fallon et al.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER'S Initial of reference document, whether or not citation is in accordance with MPEP 2009. Date here through check of use in examinations and not considered. Include copy of use form with each communication to applicant. *Applicant's unique citation designation number (optional). *See Kinda Office of USPTO Patent Documents at www.uspto.gov or MPEP 601.04. *Patent Office that issued this document, by the two-letter code (USPTO Standard SI 1). *For Japanese patent documents, the indication of the year of the filing of the application must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the appropriate codes (USPTO Standard SI 1.6 if possible). *Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.07 and 1.58. The information is required to obtain or make a benefit by the public which is to be used by the USPTO to process an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is submitted to take 2 hours to complete, including searching, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any equivalent to the amount of time you remove to complete this form before submitting, for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 488, Alexandria, VA 22313-1450. DO NOT SEND FORMS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Correspondence for Patents, P.O. Box 488, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9799 (2-800-786-4199) and select option 2.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/990,909
				Filing Date	November 16, 2001
				First Named Inventor	Joan M. Pallen
				Art Unit	1645
				Examiner Name	Virginia Allen Portner
Sheet	3	of	4	Attorney Docket Number	41012-705.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	T ²
	39.	BRUDNAK et al. Enzyme-based therapy for autism spectrum disorders -- is it worth another look? Med Hypoth. 2002; 58:422-428.	
	40.	Final Office Action dated 2/14/11 for US Application 12/049,613.	
	41.	HENDREN et al. Mechanistic biomarkers for autism treatment. Medical Hypotheses. 2009; 73:950-954.	
	42.	International search report and written opinion dated 1/18/11 for PCT/US2010/057341	
	43.	International search report and written opinion dated 2/15/11 for PCT/US2010/053484	
	44.	International search report and written opinion dated 6/9/10 for PCT/US2010/030895	
	45.	LIEBERMAN. Pharmaceutical Dosage Forms. Vol. 2: Disperse Systems. New York Marcel Dekker, Inc. 1996; 243-258.	
	46.	LIPASE 30, Technical Data sheet, 1 page, Scientific Protein Laboratories LLC 6/13/05	
	47.	Office Action dated 1/21/11 for US Application 12/386,051.	
	48.	Office Action dated 10/1/01 for US Application 09/466,559.	
	49.	Office Action dated 10/5/10 for US Application 12/046,402.	
	50.	Office Action dated 11/15/10 for US Application 12/238,415.	
	51.	Office Action dated 4/22/03 for US Application 09/929,592.	
	52.	Office Action dated 7/22/10 for US Application 12/049,613.	
	53.	Office Action dated 8/13/02 for US Application 09/929,592.	
	54.	Office Action dated 8/20/10 for US Application 12/283,090.	
	55.	Office Action dated 8/25/10 for US Application 12/487,868.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial of reference considered, whether or not citation is in accordance with MPEP 609. /Draw file through citation if not in correspondence and not unaltered. /Include copy of Use form with new correspondence to applicant. /Applicant is to place a checkmark here if English language Translation is attached.

*Applicant's unique citation designations number (optional). /Applicant is to place a checkmark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 CFR 1.54, 122 and 37 CFR 1.14. This collection is intended to take 4 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Also, comments on the section of lines you require to complete this form, and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1480, Alexandria, VA 22313-1480. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1480, Alexandria, VA 22313-1480.

(If you need assistance in completing the form, call 1-800-PTO-9999 /1-800-766-9999 and select option 3.

Substitute for form 1449/PTO				<div>Complete if Known</div> <div>Application Number 09/990,909</div> <div>Filing Date November 16, 2001</div> <div>First Named Inventor Joan M. Fallon</div> <div>Art Unit 1645</div> <div>Examiner Name Virginia Allen Portner</div>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>					
Sheet	4	of	4	Attorney Docket Number	41012-705.201

Examiner initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	72
	56.	Pancreatic Enzyme Concentrate (PEC) Undiluted, Technical Data Sheet. 1 page, Scientific Protein Laboratories LLC 6/13/05	
	57.	Pancreatin 4X USP, Technical Data Sheet, 1 page, Scientific Protein laboratories LLC 6/13/05	
	58.	SCHRECK et al. Food preferences and factors influencing food selectivity for children with autism spectrum disorders. Res Develop Disabil. 2006; 27:353-363.	
	59.	STEIN, et a. Nitrogen Metabolism in normal and hyperkinetic boys. Am J Clin Nutr. 1984; 39:520-524.	
	60.	USP (32)-NF(27) 2009, Pancreatin, V.3, pp.3194-3195.	
	61.	WENDER et al. Prevalence of attention deficit disorder, residual type, and other psychiatric disorders in patients with irritable colon syndrome. Am J Psychiatry. 1983; 140(12): 1579-82. Abstract only.	

Examiner Signature	/Albert M Navarro/	Date Considered	05/19/2011
-----------------------	--------------------	--------------------	------------

This publication is a translation of the original Russian text. Significant is to place a footnote below the English language translation is enclosed.

This collection of information is requested by 37 CFR 1.18. The information is reported in plain text to ensure that the public interest is as fast as the USPTO is provided as appropriate. Confidentiality is guaranteed by 35 U.S.C. 186, which provides that the information is not to be disclosed to the public without the consent of the USPTO. This will only be depending upon the USPTO's own. Any comments on the original or the translation of the information should be sent to the USPTO's Office of the Chief Information Officer, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND PAGES OR COMPLETED FORMS TO THIS ADDRESS: RPNB 100, Communications for Business, P.O. Box 1450, Alexandria, VA 22313-1450.

4304739 : EXOC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MN/